About AbbVie Inc.
https://www.abbvie.comAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
CEO
Robert A. Michael CPA
Compensation Summary
(Year 2024)
Salary $1,607,404
Stock Awards $7,915,762
Option Awards $1,888,269
Incentive Plan Pay $4,590,000
All Other Compensation $482,096
Total Compensation $18,492,517
Industry Drug Manufacturers - General
Sector Healthcare
Went public January 2, 2013
Method of going public IPO
Full time employees 55,000
ETFs Holding This Stock
Summary
Total 1,063
Showing Top 3 of 1,063
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 3
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
HSBC
Buy
Guggenheim
Buy
Berenberg
Buy
Truist Securities
Buy
Raymond James
Outperform
Evercore ISI Group
Outperform
Grade Summary
Buy 4
Outperform 3
Overweight 5
Neutral 3
Showing Top 6 of 15
Price Target
Target High $289
Target Low $240
Target Median $256
Target Consensus $258.71
Institutional Ownership
VANGUARD GROUP INC
Shares:177.75M
Value:$39.44B
BLACKROCK, INC.
Shares:145.98M
Value:$32.39B
BLACKROCK INC.
Shares:136.43M
Value:$30.27B
Summary
% Of Shares Owned 53.97%
Total Number Of Holders 4,961
Showing Top 3 of 4,961
Market Cap $396.09 B
52w High $244.81
52w Low $164.39
Dividend Yield 2.95%
Frequency Quarterly
P/E 168.1
Volume 7.36M
Outstanding Shares 1.77B
About AbbVie Inc.
https://www.abbvie.comAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $15.78B ▲ | $7.5B ▲ | $186M ▼ | 1.18% ▼ | $0.1 ▼ | $3.44B ▼ |
| Q2-2025 | $15.42B ▲ | $7.16B ▲ | $944M ▼ | 6.12% ▼ | $0.53 ▼ | $4.34B ▼ |
| Q1-2025 | $13.34B ▼ | $5.61B ▼ | $1.29B ▲ | 9.64% ▲ | $0.72 ▲ | $4.4B ▲ |
| Q4-2024 | $15.1B ▲ | $12.2B ▲ | $-22M ▼ | -0.15% ▼ | $-0.02 ▼ | $535M ▼ |
| Q3-2024 | $14.46B | $6.42B | $1.56B | 10.8% | $0.88 | $4.88B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.67B ▼ | $133.9B ▼ | $136.5B ▼ | $-2.64B ▼ |
| Q2-2025 | $6.47B ▲ | $137.18B ▲ | $137.32B ▲ | $-183M ▼ |
| Q1-2025 | $5.18B ▼ | $136.16B ▲ | $134.7B ▲ | $1.42B ▼ |
| Q4-2024 | $5.55B ▼ | $135.16B ▼ | $131.8B ▼ | $3.33B ▼ |
| Q3-2024 | $7.29B | $143.42B | $137.35B | $6.03B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $188M ▼ | $7.02B ▲ | $-3.26B ▼ | $-4.59B ▼ | $-838M ▼ | $7.53B ▲ |
| Q2-2025 | $941M ▼ | $5.15B ▲ | $-1.18B ▼ | $-2.71B ▼ | $1.29B ▲ | $4.88B ▲ |
| Q1-2025 | $1.29B ▼ | $1.64B ▼ | $-735M ▲ | $-1.26B ▲ | $-349M ▲ | $1.4B ▼ |
| Q4-2024 | $4.29B ▲ | $7.05B ▲ | $-1.87B ▲ | $-6.86B ▼ | $-1.73B ▲ | $6.76B ▲ |
| Q3-2024 | $1.59B | $5.45B | $-8.26B | $-3.07B | $-5.87B | $5.2B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 AlphaganCombigan | $80.00M ▲ | $60.00M ▼ | $40.00M ▼ | $50.00M ▲ |
 Botox Cosmetic | $690.00M ▲ | $560.00M ▼ | $690.00M ▲ | $640.00M ▼ |
 Botox Therapeutic | $870.00M ▲ | $870.00M ▲ | $930.00M ▲ | $980.00M ▲ |
 Duodopa | $110.00M ▲ | $100.00M ▼ | $100.00M ▲ | $100.00M ▲ |
 H U M I R A | $1.68Bn ▲ | $1.12Bn ▼ | $1.18Bn ▲ | $990.00M ▼ |
 Imbruvica | $850.00M ▲ | $740.00M ▼ | $750.00M ▲ | $710.00M ▼ |
 Juvederm Collection | $280.00M ▲ | $230.00M ▼ | $260.00M ▲ | $250.00M ▼ |
 LinzessConstella | $230.00M ▲ | $150.00M ▼ | $260.00M ▲ | $330.00M ▲ |
 LumiganGanfort | $120.00M ▲ | $110.00M ▼ | $100.00M ▼ | $100.00M ▲ |
 MAVYRET | $290.00M ▲ | $310.00M ▲ | $380.00M ▲ | $310.00M ▼ |
 Other Aesthetics | $330.00M ▲ | $320.00M ▼ | $330.00M ▲ | $300.00M ▼ |
 Other Eye Care | $210.00M ▲ | $220.00M ▲ | $250.00M ▲ | $250.00M ▲ |
 Other Neuroscience | $100.00M ▲ | $60.00M ▼ | $60.00M ▲ | $50.00M ▼ |
 Other Products | $750.00M ▲ | $750.00M ▲ | $600.00M ▼ | $660.00M ▲ |
 Ozurdex | $120.00M ▲ | $120.00M ▲ | $130.00M ▲ | $120.00M ▼ |
 Qulipta | $200.00M ▲ | $190.00M ▼ | $270.00M ▲ | $290.00M ▲ |
 RINVOQ | $1.83Bn ▲ | $1.72Bn ▼ | $2.03Bn ▲ | $2.18Bn ▲ |
 SKYRIZI | $3.78Bn ▲ | $3.42Bn ▼ | $4.42Bn ▲ | $4.71Bn ▲ |
 Ubrelvy | $300.00M ▲ | $240.00M ▼ | $340.00M ▲ | $350.00M ▲ |
 VENCLEXTA | $660.00M ▲ | $670.00M ▲ | $690.00M ▲ | $730.00M ▲ |
 Vraylar | $920.00M ▲ | $770.00M ▼ | $900.00M ▲ | $930.00M ▲ |
 Restasis | $110.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 NonUS | $3.37Bn ▲ | $630.00M ▼ | $9.98Bn ▲ | $580.00M ▼ |
 UNITED STATES | $11.73Bn ▲ | $4.23Bn ▼ | $3.36Bn ▼ | $3.84Bn ▲ |
CEO
Robert A. Michael CPA
Compensation Summary
(Year 2024)
Salary $1,607,404
Stock Awards $7,915,762
Option Awards $1,888,269
Incentive Plan Pay $4,590,000
All Other Compensation $482,096
Total Compensation $18,492,517
Industry Drug Manufacturers - General
Sector Healthcare
Went public January 2, 2013
Method of going public IPO
Full time employees 55,000
ETFs Holding This Stock
Summary
Total 1,063
Showing Top 3 of 1,063
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 3
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
HSBC
Buy
Guggenheim
Buy
Berenberg
Buy
Truist Securities
Buy
Raymond James
Outperform
Evercore ISI Group
Outperform
Grade Summary
Buy 4
Outperform 3
Overweight 5
Neutral 3
Showing Top 6 of 15
Price Target
Target High $289
Target Low $240
Target Median $256
Target Consensus $258.71
Institutional Ownership
VANGUARD GROUP INC
Shares:177.75M
Value:$39.44B
BLACKROCK, INC.
Shares:145.98M
Value:$32.39B
BLACKROCK INC.
Shares:136.43M
Value:$30.27B
Summary
% Of Shares Owned 53.97%
Total Number Of Holders 4,961
Showing Top 3 of 4,961